Tremelimumab for Malignant Mesothelioma

Phase-Based Progress Estimates
Research Site, Candiolo, ItalyMalignant MesotheliomaTremelimumab - Drug
18 - 99
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new cancer drug for people with mesothelioma who can't have surgery. 564 people will be enrolled and randomly assigned to either receive the drug or a placebo. There will be follow-ups to check safety and long-term effects.

Eligible Conditions
  • Malignant Mesothelioma

Treatment Effectiveness

Study Objectives

1 Primary · 9 Secondary · Reporting Duration: 3 years.

18 months
OS Rate at 18 Months by Treatment Arm
3 years.
Overall Survival (OS)
Day 90
Number of Participants Reporting Any Serious Adverse Events
Day 90
Number of Participants Reporting Any Adverse Event
Week 14
Upper arm
Year 3
Overall Response Rate by Treatment Arm
Year 3
Disease Control Rate by Treatment Arm
Upper arm
Upper arm
Week 5
Number of Participants With Positive Anti-drug Antibodies

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Side Effects for

Durvalumab and Tremelimumab
17%Maculopapular rash
14%Rash maculo-papular
10%Abdominal pain
7%Non-cardiac chest pain
7%Dry Skin
7%Weight loss
This histogram enumerates side effects from a completed 2019 Phase 2 trial (NCT03007407) in the Durvalumab and Tremelimumab ARM group. Side effects include: Fatigue with 38%, Diarrhea with 21%, Anorexia with 17%, Pruritus with 17%, Maculopapular rash with 17%.

Trial Design

2 Treatment Groups

1 of 2
1 of 2

Experimental Treatment

Non-Treatment Group

571 Total Participants · 2 Treatment Groups

Primary Treatment: Tremelimumab · Has Placebo Group · Phase 2

Experimental Group · 1 Intervention: Tremelimumab · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Not yet FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years.

Who is running the clinical trial?

MedImmune LLCLead Sponsor
347 Previous Clinical Trials
793,235 Total Patients Enrolled

Eligibility Criteria

Age 18 - 99 · All Participants · 11 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Your disease cannot be treated with surgery that can cure it.

Frequently Asked Questions

Does the age limit for this research extend beyond 65 years old?

"The specific age range for this clinical trial is much larger than average, as it encompasses patients from 18 to 99 years old. There are 49 other trials underway for people who are under 18 and 1742 different ones for patients over 65." - Anonymous Online Contributor

Unverified Answer

Are there any positions available for participants in this research?

"Currently, this study is not looking for new patients according to the website. The trial was first posted on May 17th, 2013 and last edited on August 30th, 2022. Even though this specific study isn't taking candidates, there are 1,749 other trials that are actively recruiting right now." - Anonymous Online Contributor

Unverified Answer

Is Tremelimumab a new or experimental medication?

"Tremelimumab was first investigated in 2007 at Research Site. Since then, there have been 18353 completed studies on the medication. As of now, 94 clinical trials are ongoing; a majority of these are located in Sainte Foy, Quebec." - Anonymous Online Contributor

Unverified Answer

Is this a ground-breaking clinical trial?

"Tremelimumab has been under medical research scrutiny since 2007. A trial was completed in that year, with AstraZeneca footing the bill. 37 people were involved in the first study. After Phase 2 drug approval, 94 active studies involving 263 cities and 48 countries began to use Tremelimumab." - Anonymous Online Contributor

Unverified Answer

In how many different medical clinics is this clinical study being conducted today?

"Currently, this clinical trial is enrolling patients at 22 sites which are situated in cities including Sainte Foy, Philadelphia and La Jolla. If you choose to enroll in the trial, it may be advantageous to select a location nearest to you so as to reduce travel time commitment." - Anonymous Online Contributor

Unverified Answer

What is the limit to how many patients can join this experiment?

"Unfortunately, this study is no longer admitting patients. The listing was created on May 17th, 2013 and last updated on August 20th, 2022. For those still seeking studies, there are 1655 active clinical trials for lung cancer and 94 actively enrolling Tremelimumab candidates." - Anonymous Online Contributor

Unverified Answer

What have been the most common side effects that patients experience with Tremelimumab?

"Tremelimumab's safety is rated as a 2 by our team at Power. While there isn't data attesting to its efficacy, tremelimumab has undergone some clinical trials that support its safety." - Anonymous Online Contributor

Unverified Answer

How can I get involved with this clinical trial?

"The ideal candidate for this particular clinical trial would be between the ages of 18 and 99, has a diagnosis of lung cancer, and there are 571 total patients being sought." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.